vir-7831
mAbexperimental
Clinical trial activity
5 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Jul 3, 2020 (NCT04746183)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04913675 | Phase 3 | Jun 10, 2021 | GlaxoSmithKline, Vir Biotechnology, Inc. |
| NCT05780281 | Phase 3 | Dec 16, 2020 | AIDS Clinical Trials Group, Cardiothoracic Surgical Trials Network, Department of Veteran Affairs, GlaxoSmithKline, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), Medical Research Council, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), University of Copenhagen, University of Minnesota, University of New South Wales, Vir Biotechnology, Inc. |
| NCT04545060 | Phase 2/Phase 3 (Phase 3) | Aug 27, 2020 | GlaxoSmithKline, Vir Biotechnology, Inc. |
| NCT04501978 | Phase 3 | Aug 4, 2020 | Brii Biosciences, Department of Veteran Affairs, Eli Lilly, GlaxoSmithKline, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), Medical Research Council, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), University of Copenhagen, University of Minnesota, University of New South Wales, Vir Biotechnology, Inc. |
| NCT04746183 | Phase 1/Phase 2 (Phase 2) | Jul 3, 2020 | Moorgreen Hospital, Southampton, Royal Liverpool & Broadgreen University Hospitals NHS Truts, University of Cambridge, University of Liverpool |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (18)
18 organizations
Page 1 / 1